EVENTS | VIEW CALENDAR
Extending its reach
HOUSTON—In an effort to expand its research and development footprint, Emerging Healthcare Solutions Inc. recently announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama.
Financial terms of the deal have not been released.
Houston-based EHSI initially signed a profit participation agreement with the company in March.
Headquartered in Panama City, Panama, Celulas Genetica is a Central American leader in stem cell technology acquisition and development.
In early December, Celulas Genetica purchased a license to develop and market the revolutionary Rutherford Procedure, a groundbreaking organ regeneration treatment designed to use proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells.
"Celulas Genetica's license to develop and market the Rutherford Procedure was our main motivator to complete this acquisition," points out EHSI President and CEO Cindy Morrissey. "We intend to test this innovative procedure thoroughly and develop it into a viable treatment for deadly illnesses such as liver disease. The worldwide demand for stem cell therapies of this kind is extraordinary."
Celulas Genetica is currently exploring the possibility of working with a Chinese proton therapy facility to develop the new treatment for use around the globe.
In the wake of the acquisition, EHSI announced that Celulas Genetica would submit an international patent application for the Rutherford Procedure.
Celulas Genetica has engaged a patent specialist to file the Patent Cooperation Treaty (PTC) application with a receiving office in China, the company noted.
The biotech company licensed the procedure from a Chinese firm, BBFITCL, and plans to conduct the treatment's clinical trials in China, as well.
"We believe that the Rutherford Procedure could very well revolutionize the treatment of liver disease worldwide," Morrissey notes. "Filing a PTC application is a necessary step to protect the value of this crucial asset."
Morrissey says that she plans to travel to China soon to meet with stem-cell researchers and potentially help open a Celulas Genetica business office there.
According to Morrissey, extending its reach into the R&D hotbed of China would build on EHSI's expanding global footprint.
Celulas Genetica will be only the latest outpost in EHSI's global footprint. In addition to its Houston headquarters, the company also maintains business offices in Frankfurt, Germany and Warsaw, Poland. "Much of the top stem cell research being conducted today takes place outside the United States," Morrissey points out. "To be an industry leader in this field, you have to be international, and we fully intend to fund and produce industry-leading innovations."